title: Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect.
authors.affiliation: Cardiology Department, State University of Campinas (Unicamp), Campinas, SP, Brazil. Electronic address: luizsergiofc@gmail.com.
authors.forename: Luiz Sérgio F
authors.initials: LS
authors.lastname: de Carvalho
authors.affiliation: Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Chiba, Japan. Electronic address: hyoshida@jikei.ac.jp.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
mesh_terms: D000924:Anticholesteremic Agents; D004359:Drug Therapy, Combination; D050171:Dyslipidemias; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia; D000071449:Proprotein Convertase 9
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: Clinical trials; Hypercholesterolemia; Lipid modifying drugs; PCSK9 inhibitors